Close Menu

Drug Discovery & Development

News on drug screening, clinical trials, companion diagnostics, immunotherapy, & personalized therapies in genetics, genomics, and molecular diagnostics.

The company is using newly raised funds to support a disseminated trial model, which it said will help it keep its plans to finish the study by the end of 2021.

The funding package earmarks billions for the Public Health and Social Services Emergency Fund and Biomedical Advanced Research and Development Authority.

Caris will sequence DNA and RNA for certain cancer patients and potentially help Merus enroll cancer patients with NRG1 fusions in the Phase I/II eNRGy trial for zenocutuzumab.

The accelerated approval is based on results from two cohorts of a Phase II, single-arm trial in which EZH2-mutated patients had an overall response rate of 69 percent.

The diagnostics firm is conducting a 1,000-person study to find T cell profiles associated with the immune response to COVID-19 and recovery from the disease.